Deciphering Disease: How Exome Sequencing Targets the Genes That Matter Most

Exome sequencing (ES) has revolutionised clinical diagnostics by targeting the protein-coding regions of DNA. Although these regions represent a minority of the genome, they contain a vast number of well-characterised pathogenic mutations. By focusing resources here, scientists can precisely identify variants linked to rare diseases and cancer more efficiently than by sequencing the entire genome.

The review outlines a sophisticated workflow involving DNA extraction, library preparation, and computational analysis using tools like GATK and DeepVariant. Beyond standard diagnostics, ES is expanding into pharmacogenomics—examining how genes like CYP2C19 affect drug metabolism—and integrative studies combining transcriptomic and proteomic data. Emerging technologies now include long-read systems and machine learning prioritisation to improve accuracy.

Despite its promise, the field faces hurdles such as complex variant interpretation, false positives, and the need for rigorous data standardisation. Ethical considerations regarding informed consent and data privacy (adhering to regulations like GDPR) remain critical. As bioinformatics infrastructures scale up, ES is cementing its status as a pivotal tool for the era of personalised medicine.